Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 50,000 shares at $163.47 ($8.2M) on 2014-12-24, disclosed to the SEC on 2014-12-29.
Scheduled sale ($8.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $160.59 | 6,670 | $1.1M | 13.1% |
| 2 | $161.77 | 10,343 | $1.7M | 20.5% |
| 3 | $162.58 | 9,394 | $1.5M | 18.7% |
| 4 | $163.55 | 5,118 | $837K | 10.2% |
| 5 | $165.22 | 1,600 | $264K | 3.2% |
| 6 | $165.86 | 150 |
| $25K |
| 0.3% |
| 7 | $162.21 | 500 | $81K | 1.0% |
| 8 | $163.47 | 422 | $69K | 0.8% |
| 9 | $164.69 | 2,499 | $412K | 5.0% |
| 10 | $165.67 | 4,832 | $801K | 9.8% |
| 11 | $166.54 | 5,086 | $847K | 10.4% |
| 12 | $167.33 | 78 | $13K | 0.2% |
| 13 | $165.34 | 800 | $132K | 1.6% |
| 14 | $166.43 | 2,408 | $401K | 4.9% |
| 15 | $167.25 | 100 | $17K | 0.2% |
| Total | $163.40 avg | 50,000 | $8.2M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |